72 related articles for article (PubMed ID: 37200112)
41. An update on the safety of nivolumab for the treatment of advanced melanoma.
Czarnecka AM; Rutkowski P
Expert Opin Drug Saf; 2020 Apr; 19(4):409-421. PubMed ID: 32293935
[No Abstract] [Full Text] [Related]
42. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
43. Relatlimab-nivolumab: A practical overview for dermatologists.
Mullick N; Nambudiri VE
J Am Acad Dermatol; 2023 Nov; 89(5):1031-1037. PubMed ID: 37343829
[TBL] [Abstract][Full Text] [Related]
44. Nivolumab: A Review in Advanced Melanoma.
Scott LJ
Drugs; 2015 Aug; 75(12):1413-24. PubMed ID: 26220912
[TBL] [Abstract][Full Text] [Related]
45. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
Hayashi H; Nakagawa K
Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
[TBL] [Abstract][Full Text] [Related]
46. Intralesional and systemic immunotherapy for metastatic melanoma.
Luu C; Khushalani NI; Zager JS
Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
[TBL] [Abstract][Full Text] [Related]
47. The introduction of LAG-3 checkpoint blockade in melanoma: immunotherapy landscape beyond PD-1 and CTLA-4 inhibition.
Kreidieh FY; Tawbi HA
Ther Adv Med Oncol; 2023; 15():17588359231186027. PubMed ID: 37484526
[TBL] [Abstract][Full Text] [Related]
48. Nivolumab (OPDIVOO) BRAF V600 mutation-negative metastatic or inoperable melanoma: survival advantage.
Prescrire Int; 2016 Dec; 25(177):289-292. PubMed ID: 30758924
[TBL] [Abstract][Full Text] [Related]
49. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
50. The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review.
Moujaess E; Haddad FG; Eid R; Kourie HR
Immunotherapy; 2019 Nov; 11(16):1409-1422. PubMed ID: 31621445
[TBL] [Abstract][Full Text] [Related]
51. Anti-PD-1 immunotherapy in advanced metastatic melanoma: State of the art and future challenges.
Moreira RS; Bicker J; Musicco F; Persichetti A; Pereira AMPT
Life Sci; 2020 Jan; 240():117093. PubMed ID: 31760100
[TBL] [Abstract][Full Text] [Related]
52. Checkpoint immunotherapy by nivolumab for treatment of metastatic melanoma.
Koppolu V; Rekha Vasigala VK
J Cancer Res Ther; 2018; 14(6):1167-1175. PubMed ID: 30488824
[TBL] [Abstract][Full Text] [Related]
53. Relatlimab: a novel drug targeting immune checkpoint LAG-3 in melanoma therapy.
Su J; Fu Y; Cui Z; Abidin Z; Yuan J; Zhang X; Li R; Zhao C
Front Pharmacol; 2023; 14():1349081. PubMed ID: 38269271
[TBL] [Abstract][Full Text] [Related]
54. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
55. The safety of nivolumab for the treatment of metastatic melanoma.
O'Reilly A; Larkin J
Expert Opin Drug Saf; 2017 Aug; 16(8):955-961. PubMed ID: 28679287
[TBL] [Abstract][Full Text] [Related]
56. Nivolumab plus ipilimumab in metastatic melanoma: a critical appraisal focused on specific subpopulations.
Vázquez-Montero L; de la Gala MDCÁ; de la Cruz-Merino L
Front Oncol; 2023; 13():1187840. PubMed ID: 37404764
[TBL] [Abstract][Full Text] [Related]
57. Single versus combination immunotherapy drug treatment in melanoma.
Grimaldi AM; Marincola FM; Ascierto PA
Expert Opin Biol Ther; 2016; 16(4):433-41. PubMed ID: 26642234
[TBL] [Abstract][Full Text] [Related]
58. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma.
Spain L; Larkin J
Expert Opin Biol Ther; 2016; 16(3):389-96. PubMed ID: 26750801
[TBL] [Abstract][Full Text] [Related]
59. Nivolumab in melanoma.
Specenier P
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1247-1261. PubMed ID: 27776441
[TBL] [Abstract][Full Text] [Related]
60. Monoclonal Antibodies for the Treatment of Melanoma: Present and Future Strategies.
Bhandaru M; Rotte A
Methods Mol Biol; 2019; 1904():83-108. PubMed ID: 30539467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]